Virology
HIV values remain stable in hepatitis C coinfected patients on peginterferon
Published in AIDS Weekly, August 8th, 2005
"We evaluated the safety and efficacy of peginterferon alpha-2a (pegIFN alpha-2a), with or without ribavirin, in 154 hepatitis C virus/human immunodeficiency virus (HCV/HIV) coinfected patients. All received pegIFN alpha-2a (180 mcg/week) for 12 weeks, with those achieving an early virologic response (EVR) continued on monotherapy through week 48," researchers in the United States report.
"Patients without an EVR were randomized at week 14 to also receive ribavirin (800 mg/day) or placebo through week 48. Patients with detectable HCV RNA at week 24 were discontinued,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-08-08)
More Articles from AIDS Weekly
- HIV/AIDS & Dengue Fever
Dendritic cell precursors are permissive to dengue virus and HIV infection - HIV/AIDS Drug Development
Artificial zinc finger fusions repress HIV-1 transcription and replication - HIV/AIDS HAART
Risk of triple-class antiretroviral drug failure declining in Denmark - HIV/AIDS Pathogenesis
Resting naive CD4+ cells massively infected/eliminated by X4-tropic SHIV - HIV/AIDS Treatment
High degree on agreement of HIV treatment recommendations derived from genotypes - Avian Influenza
International health entity stresses threat from Avian influenza has not ebbed - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
